19,694 Shares in Exelixis, Inc. $EXEL Acquired by FCG Investment Co

FCG Investment Co bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 2nd quarter, Holdings Channel.com reports. The firm bought 19,694 shares of the biotechnology company’s stock, valued at approximately $868,000.

Several other institutional investors have also added to or reduced their stakes in the business. Belpointe Asset Management LLC bought a new stake in shares of Exelixis during the 1st quarter valued at $572,000. GAMMA Investing LLC lifted its position in Exelixis by 32.2% during the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 1,328 shares in the last quarter. Park Avenue Securities LLC grew its holdings in Exelixis by 10.6% during the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company’s stock valued at $272,000 after purchasing an additional 707 shares during the period. Envestnet Asset Management Inc. increased its position in Exelixis by 23.9% in the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after buying an additional 47,845 shares in the last quarter. Finally, Fortis Capital Advisors LLC bought a new position in shares of Exelixis in the first quarter worth about $572,000. 85.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Bank of America boosted their price objective on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 5th. Royal Bank Of Canada reduced their price objective on shares of Exelixis from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 29th. Stifel Nicolaus lifted their target price on shares of Exelixis from $38.00 to $41.00 and gave the company a “hold” rating in a research note on Tuesday, July 29th. Stephens raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Finally, Jefferies Financial Group set a $50.00 price target on Exelixis and gave the company a “buy” rating in a report on Tuesday, June 24th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $44.42.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $38.69 on Friday. The company has a market cap of $10.42 billion, a P/E ratio of 18.60, a P/E/G ratio of 0.80 and a beta of 0.32. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The firm’s fifty day moving average is $39.08 and its two-hundred day moving average is $39.70.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the prior year, the firm earned $0.84 EPS. The business’s revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. As a group, analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.